RxDoctor Payments DataLook up a doctor →

Abhimanyu Ghose, MD

Internal Medicine · Gilbert, AZNPI 1649400581

Payments from drug & device makers

$758,416in general payments, 2019–2025

Across 551 payments — averaging $1376.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$239K
  • E.r. Squibb & Sons, L.L.C.$198K
  • Incyte Corporation$102K
  • Pfizer$61K
  • AstraZeneca$36K
  • Eli Lilly$26K
  • plus $97K from 54 others

What the payments were for

  • Consulting fees$50,92670%
  • Speaking & faculty fees$5,4858%
  • Travel & lodging$8,06711%
  • Food & beverage$7,59910%
  • Education$9051%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.41$238,789
E.r. Squibb & Sons, L.L.C.41$197,976
Incyte Corporation69$102,185
Pfizer32$60,836
AstraZeneca(2 entities)27$35,680
Eli Lilly3$26,350
Merck48$20,473
Bristol Myers Squibb24$17,313
Novartis41$14,338
Eisai Inc.24$8,929
Seagen Inc.6$5,236
AbbVie23$5,203
Acceleron Pharma, Inc.2$4,495
Beigene USA, Inc.2$2,800
Karyopharm Therapeutics Inc.5$2,650
Sanofi13$2,542
Verastem, Inc.5$2,408
ADC Therapeutics America, Inc.1$2,400
Heron Therapeutics, Inc.1$1,800
Bayer9$1,752
Johnson & Johnson16$460
Astellas Pharma US Inc6$404
Daiichi Sankyo Inc.2$388
Novocure Inc.4$358
Genentech USA, Inc.18$347
Gilead(2 entities)11$299
Mirati Therapeutics, Inc.4$169
Takeda Pharmaceuticals U.S.A., Inc.6$162
Amgen5$113
Regeneron Healthcare Solutions, Inc.4$106
Sun Pharmaceutical Industries Inc.1$104
Intuitive Surgical2$97
Janssen Scientific Affairs, LLC2$88
Rigel Pharmaceuticals, Inc.2$83
Puma Biotechnology, Inc.5$81
Lilly USA, LLC4$69
EMD Serono, Inc.2$65
Array Biopharma Inc3$53
Sanofi-aventis U.S. LLC1$50
GSK2$49
Ipsen Biopharmaceuticals, Inc2$43
GE HealthCare1$43
Pharmacyclics LLC, An Abbvie Company2$40
Sobi, Inc1$36
Mylan Institutional Inc.2$36
Lexicon Pharmaceuticals, Inc.2$34
Genmab U.S., Inc.1$33
Teva Pharmaceuticals USA, Inc.2$33
Foundation Medicine, Inc.1$31
Clovis Oncology, Inc.2$30
Beone Medicines USA, Inc.1$29
AMAG Pharmaceuticals, Inc.2$29
Progenics Pharmaceuticals, Inc.1$28
Springworks Therapeutics, Inc.1$28
Sumitomo Pharma America, Inc.1$25
Pharmaessentia USA Corporation1$25
Kyowa Kirin, Inc.1$24
Helsinn Therapeutics (U.S.), Inc.2$24
Legend Biotech USA Inc.1$24
Dendreon Pharmaceuticals LLC1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$758,416 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$126,141
Medicare patients
342
Services billed
1,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide51$1,046,274
JakafiRuxolitinib Phosphate52$748,798
CalquenceAcalabrutinib Maleate24$346,704
Lenalidomide27$341,604
XtandiEnzalutamide24$294,921
TabrectaCapmatinib Hydrochloride12$274,541
NubeqaDarolutamide27$258,289
SprycelDasatinib14$256,736
ImbruvicaIbrutinib13$203,572
ErleadaApalutamide13$194,130
BrukinsaZanubrutinib20$189,282
EliquisApixaban111$117,902
Bexarotene12$86,943
XareltoRivaroxaban39$55,916
Abiraterone Acetate44$35,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$17,313$1,046,27451 claims
Incyte CorporationJakafi$102,185$748,79852 claims
AstraZenecaCalquence$35,680$346,70424 claims
Astellas Pharma US IncXtandi$404$294,92124 claims
NovartisTabrecta$14,338$274,54112 claims
BayerNubeqa$1,752$258,28927 claims
E.r. Squibb & Sons, L.L.C.Sprycel$197,976$256,73614 claims
Johnson & JohnsonErleada, Xarelto$460$250,04752 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$40$203,57213 claims
Beigene USA, Inc.Brukinsa$2,800$189,28220 claims
PfizerEliquis$60,836$117,902111 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$88$35,68044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →